Boronated monoclonal antibodies for potential neutron capture therapy of malignant melanoma and leukaemia
Tamat, S.R.; Patwardhan, A.; Moore, D.E.; Kabral, A.; Bradstock, K.; Hersey, P.; Allen, B.J.
Strahlentherapie und Onkologie Organ der Deutschen Rontgengesellschaft . 165(2-3): 145-147
1989
ISSN/ISBN: 0179-7158 PMID: 2494717 Document Number: 328640
Document emailed within 1 workday
Related Documents
Laster, B.H.; Kahl, S.B.; Popenoe, E.A.; Pate, D.W.; Fairchild, R.G. 1991: Biological efficacy of boronated low-density lipoprotein for boron neutron capture therapy as measured in cell culture Cancer Research 51(17): 4588-4593Matalka, K.Z.; Bailey, M.Q.; Barth, R.F.; Staubus, A.E.; Soloway, A.H.; Moeschberger, M.L.; Coderre, J.A.; Rofstad, E.K. 1993: Boron neutron capture therapy of intracerebral melanoma using boronophenylalanine as a capture agent Cancer Research 53(14): 3308-3313
Takagaki, M.; Ono, K.; Oda, Y.; Kikuchi, H.; Nemoto, H.; Iwamoto, S.; Cai, J.; Yamamoto, Y. 1996: Hydroxylforms of p-boronophenylalanine as potential boron carriers on boron neutron capture therapy for malignant brain tumors Cancer Research 56(9): 2017-2020
Allen, B.J. 1990: The potential of neutron capture therapy in the management of uncontrollable localised tumours Australasian Radiology 34(4): 297-305
Yong, J.H.; Barth, R.F.; Wyzlic, I.M.; Soloway, A.H.; Rotaru, J.H. 1995: In vitro and in vivo evaluation of o-carboranylalanine as a potential boron delivery agent for neutron capture therapy Anticancer Research 15(5b): 2033-2038
Wambersie, A.; Menzel, H.G. 1993: RBE in fast neutron therapy and in boron neutron capture therapy. a useful concept or a misuse? Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft . 169(1): 57-64
Montagno, E.d.A.; Moreira Filho, L.; Hatanaka, H. 1989: Three cases of terminal stage malignant gliomas in which the diffusely disseminated intraventricular tumors became the target of boron neutron capture therapy Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft . 165(2-3): 238-240
Gahbauer, R.; Kanellitsas, C.; Blue, T.; Wang, C.; Clendenon, N.; Fairchild, R.; Laster, B.; McGregor, J.; Goodman, J. 1989: Dose bracketing in boron neutron capture therapy Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft . 165(2-3): 229-230
Hatanaka, H.; Amano, K.; Sano, K.; Mogami, H.; Hayakawa, T. 1974: Boron-10-slow neutron capture therapy for brain tumors No Shinkei Geka. Neurological Surgery 2(1): 7-16
Hatanaka, H.; Sano, K.; Yasukochi, H. 1988: Boron-neutron capture therapy in brain tumors and other cancers--a radiosurgery Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(4 Pt: 2-2): 1115-1123
Spitler, L.E.; del Rio, M.; Khentigan, A.; Wedel, N.I.; Brophy, N.A.; Miller, L.L.; Harkonen, W.S.; Rosendorf, L.L.; Lee, H.M.; Mischak, R.P. 1987: Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin a chain immunotoxin Cancer Research 47(6): 1717-1723
Matsumura, A.; Zhang, T.; Nakai, K.; Endo, K.; Kumada, H.; Yamamoto, T.; Yoshida, F.; Sakurai, Y.; Yamamoto, K.; Nose, T. 2005: Combination of boron and gadolinium compounds for neutron capture therapy. An in vitro study Journal of Experimental and Clinical Cancer Research: Cr 24(1): 93-98
Cheung, N.K.; Saarinen, U.; Neely, J.; Miraldi, F.; Strandjord, S.; Warkentin, P.; Coccia, P. 1985: Development of neuroblastoma monoclonal antibodies for potential utilization in diagnosis and therapy Progress in Clinical and Biological Research 175: 501-505
Mill, A.J. 1989: Biological effects of intermediate-energy neutrons and their relevance to boron neutron capture therapy Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft . 165(2-3): 193-196
Dorn, R.V.; Spickard, J.H.; Griebenow, M.L. 1989: A proposed protocol for clinical trials of boron neutron capture therapy in glioblastoma multiforme Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft . 165(2-3): 233-234
Al-Samarrai, S.F.; Takeuchi, A.; Hatanaka, H. 1975: Electron microscopic study on the response of the normal canine brain to boron-neutron capture therapy Gan 66(6): 663-672
Burchiel, S.W.; Martin, J.C.; Imai, K.; Ferrone, S.; Warner, N.L. 1982: Heterogeneity of HLA-A,B, Ia-like, and melanoma-associated antigen expression by human melanoma cell lines analyzed with monoclonal antibodies and flow cytometry Cancer Research 42(10): 4110-4115
Dreitz, M.J.; Dow, S.W.; Fiscus, S.A.; Hoover, E.A. 1995: Development of monoclonal antibodies and capture immunoassays for feline immunodeficiency virus American Journal of Veterinary Research 56(6): 764-768
Wambersie, A.; Scalliet, P. 1989: Clinical implementation in BNCT (boron neutron capture therapy): fractionated versus protracted low dose rate irradiation Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft . 165(5): 407-411
Buraggi, G.L.; Callegaro, L.; Mariani, G.; Turrin, A.; Cascinelli, N.; Attili, A.; Bombardieri, E.; Terno, G.; Plassio, G.; Dovis, M. 1985: Imaging with 131I-labeled monoclonal antibodies to a high-molecular-weight melanoma-associated antigen in patients with melanoma: efficacy of whole immunoglobulin and its F(ab')2 fragments Cancer Research 45(7): 3378-3387